



Transcranial magnetic stimulation and 
transcranial direct current stimulation appear 
to be safe neuromodulatory techniques useful 
in the treatment of anxiety disorders and 
other neuropsychiatric disorders
Uso clínico da estimulação magnética transcraniana e da estimulação transcraniana por 
corrente direta em transtornos de ansiedade e de transtornos neuropsiquiátricos
Aline Iannone1, Antonio Pedro de Mello Cruz1, Joaquim Pereira Brasil-Neto2, Raphael Boechat-Barros3
Transcranial magnetic stimulation (TMS) and transcra-
nial direct current stimulation (tDCS) are noninvasive tran-
scranial stimulation techniques recently used in the fields of 
neurology and psychiatry. Originally introduced by Barker, 
Jalinous and Freeston1, TMS has consolidated itself as an 
increasingly important technique for noninvasive stimula-
tion of the human motor cortex2. Initially used as a method 
to investigate changes in motor pathways due to neurological 
diseases and even certain neuropsychiatric disorders3, TMS 
also began to be used as a form of therapy for diseases such as 
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ABSTRACT
Transcranial magnetic stimulation (TMS) has recently been investigated as a possible adjuvant treatment for many neuropsychiatric 
disorders, and has already been approved for the treatment of drug-resistant depression in the United States and in Brazil, among other 
countries. Although its use in other neuropsychiatric disorders is still largely experimental, many physicians have been using it as an 
off-label add-on therapy for various disorders. More recently, another technique, transcranial direct current stimulation (tDCS), has also 
become available as a much cheaper and portable alternative to TMS, although its mechanisms of action are different from those of TMS. 
The use of off-label therapeutic TMS or tDCS tends to occur in the setting of diseases that are notoriously resistant to other treatment 
modalities. Here we discuss the case of anxiety disorders, namely panic and post-traumatic stress disorders, highlighting the uncertainties 
and potential problems and benefits of the clinical use of these neuromodulatory techniques at the current stage of knowledge.
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RESUMO
A estimulação magnética transcraniana (TMS) foi recentemente proposta como um possível tratamento adjuvante para muitos distúrbios 
neuropsiquiátricos, e já foi aprovada para o tratamento de depressão fármaco-resistente nos Estados Unidos e no Brasil, entre outros 
países. Apesar do fato de que seu uso em outros transtornos neuropsiquiátricos ainda é em grande parte experimental, muitos médicos 
têm utilizado essas técnicas como uma terapia off-label  em várias doenças. Mais recentemente, uma outra técnica, a estimulação 
transcraniana por corrente contínua (ETCC), tornou-se também disponível como uma alternativa muito mais barata e portátil do que a 
TMS, embora os seus mecanismos de ação sejam diferentes daqueles da TMS. O uso off-label de TMS ou ETCC tende a ocorrer no caso de 
doenças que são notoriamente resistentes a outras modalidades terapêuticas. Aqui nós discutimos o caso dos transtornos de ansiedade, 
ou seja, transtorno do pânico e  estresse pós-traumático, destacando as incertezas, benefícios e problemas potenciais inerentes ao uso 
clínico dessas técnicas neuromoduladoras no atual estágio do conhecimento.
Palavras-chave: estimulação transcraniana por corrente contínua; ansiedade; transtorno de pânico.
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Parkinson’s4, and epilepsy5. In the last two decades, research 
on using these tools to treat conditions such as depression6, 
mania7, obsessive-compulsive disorder8 and post-traumatic 
stress disorder9 began to appear.
The use of electric currents for treating psychiatric disor-
ders began in the 18th century with the development of the 
voltaic pile. However, it was only in the 1960s and 1970s that 
the noninvasive method of cerebral stimulation known as 
brain polarization, similar to modern tDCS, was able to pro-
vide improvements in mood and alertness in healthy volun-
teers, in addition to treating depression10. Later, this method 
was abandoned, possibly due to the advance of psychophar-
macology and the social stigma of electroconvulsive ther-
apy that hindered the development and emergence of new 
noninvasive forms of cerebral stimulation.
Despite the controversies involving such an early nonin-
vasive method of cerebral stimulation, tDCS began to be used 
again as a putative neuromodulatory tool in the present cen-
tury, notably with the studies of Priori10 in Italy, and Nitsche 
and Paulus11 in Germany. Both studies were able to demon-
strate that the transcranial induction of a low-intensity direct 
current, through electrodes placed on the head, increased 
(anodal stimulation) or decreased (cathodal stimulation) 
cortical excitability during the period of stimulation, suggest-
ing that tDCS probably produced its effects through chang-
es in the resting membrane potential12, thus modifying the 
threshold for firing of action potentials, or even through syn-
aptic mechanisms.
As a neuromodulatory technique, its physical and phys-
iological principles require less complex equipment than 
TMS, with only two electrodes being necessary: one cathode 
and one anode, which, arranged in different positions, cre-
ate a flow of low-intensity (1 or 2 mA) direct electric current 
that covers a specific region of the cerebral cortex, modu-
lating it in accordance to the polarity. The electric current, 
in turn, flows from one electrode to the other through the 
scalp and the cortex. By comparison, while TMS can gener-
ate strong currents capable of depolarizing the neuron un-
til it reaches the threshold for firing action potentials, tDCS 
changes cortical activity through weak electric currents, 
producing changes in the resting membrane potential, and 
consequently in brain activity13.
One fact that stands out in tDCS is the duration of its 
physiological effects. The technique is able to decrease or in-
crease cortical excitability for hours after stimulation11, prob-
ably by inducing long-term depression or long-term poten-
tiation on the treated neurons and synapses14. Due to these 
long-term changes in cortical excitability, it is commonly 
applied daily, for 20 to 30 minutes15, ensuring efficacy and 
safety. Taking into account its prolonged effects upon corti-
cal excitability, low intensity of the currents used to modu-
late brain activity, as well as the fact that it also allows sham 
stimulation in experimental protocols16, tDCS has been 
widely accepted not only as an off-label treatment but also 
as a research tool, instead of high-cost equipment such as 
magnetic stimulators. Furthermore, the technique appears 
to be quite safe, and there is no reason to-date to suspect 
tDCS to be detrimental to health17, since it presents a low 
rate of side effects when used in accordance with the stan-
dard procedures recommended by recent clinical studies for 
the treatment of psychiatric disorders. The only side effects 
associated with tDCS have been redness of the skin or mild 
superficial electrolytic burns18. However, due to the still short 
follow-up time of treated subjects, longer-term side effects, 
if any, are unknown at this time.
APPLICATIONS OF TMS AND TDCS IN PSYCHIATRY
While in the past it was necessary to surgically manipu-
late the brain in order to modulate its activity in a nonphar-
macological way, noninvasive stimulation provides some-
thing new: through TMS and tDCS, it is possible to adjust 
cerebral activity and apparently even mental processes, with 
less risk than is inherent in manipulation through neurostim-
ulator implant surgery or by using drugs19.
Due to the increasing incidence of mood disorders and 
anxiety in the global population, researchers have sought in-
creasingly effective, safe and noninvasive investigative and 
therapeutic techniques, with a lower incidence of adverse 
effects, for these disorders. According to the World Health 
Organization, depression and anxiety are among the most 
prevalent diseases in society, as per the tenth edition of the 
International Classification of Diseases (ICD-10), and are 
considered “common mental disorders” due to their high lev-
el of comorbidity and because they have similar therapeutic 
approaches. Research in the clinical field is needed in order 
to discover more effective and less invasive new treatments, 
given that not all patients respond to psychopharmacologi-
cal or psychotherapeutic interventions20.
NONINVASIVE TRANSCRANIAL STIMULATION FOR 
MAJOR DEPRESSIVE DISORDER 
Transcranial magnetic stimulation has received FDA 
approval for the treatment of major depressive disorder21. 
One notable fact is that a third of major depressive disor-
der patients are treatment-resistant, defined by the lack of 
adequate response of the symptoms after two or three an-
tidepressant treatments22. Due to the high prevalence of re-
sistance to treatment and failed antidepressant response, 
the National Institute of Mental Health developed the 
Sequenced Treatment Alternatives to Relieve Depression 
Trial, a systematic protocol for treating depression. 
According to the latter protocol, cumulative response and 
remission rates after two unsuccessful antidepressant treat-
ments are 73% and 47% respectively23. Based on these data, 
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numerous repetitive TMS (rTMS) studies have been per-
formed on the treatment of major depressive disorder and 
have shown positive results, suggesting that low-frequency 
stimulation (1Hz) of the right dorsolateral prefrontal cor-
tex, or high frequency over the left dorsolateral prefrontal 
cortex, both have antidepressant effects24. 
Double-blind studies have been developed using anodal 
tDCS on the left dorsolateral prefrontal cortex, with low in-
tensities between 1 and 2mA, over 10 days or more, and have 
shown positive results in reducing depressive symptoms25,26. 
In the study by Fregni et al.25, the results indicated a 69% im-
provement in symptoms of depression after just five sessions 
of tDCS, after 1.5 weeks, compared to a 30% improvement 
in the control group, measured on the Hamilton Depression 
Rating Scale. The same results were found by Boggio et al.26, 
with an improvement of 40.5% in the group that received 
tDCS, in comparison to 10.4% of the control group, after two 
weeks of treatment. Taking into account these promising re-
sults of tDCS as an antidepressant treatment, replication of 
these studies in the future is suggested.
EFFECTS OF TRANSCRANIAL STIMULATION UPON 
ANXIETY DISORDERS
In addition to depression, the effects of transcranial 
stimulation on anxiety disorders and related disorders have 
also been investigated. However, before discussing some 
of these studies, it should be noted that, based on the fifth 
edition of the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-V, 2014), published by the American 
Psychiatric Association, some disorders such as anxiety dis-
orders, classically recognized by the international commu-
nity, have been registered separately in this latest edition of 
the DSM, in their own chapters, with separate nosologies. 
Among these are obsessive-compulsive disorder (OCD), 
post-traumatic stress disorders (PTSD) and acute stress. 
This new and controversial classification has been the tar-
get of criticism, but it is not the purpose of this review to 
analyze its pros and cons. Thus, for the description and 
analysis of some of the main studies investigating the ef-
fects of transcranial stimulation on OCD and PTSD, before 
and after the publication of the DSM-V, a purely descriptive 
analysis of their clinical results is adopted, without consid-
ering whether or not they are anxiety disorders according 
to this version of the DSM.
NEUROMODULATION AND 
OBSESSIVE-COMPULSIVE DISORDER
Obsessive-compulsive disorder is characterized by the 
presence of obsessions and/or compulsions, where obses-
sions are thoughts, impulses or recurrent and persistent 
images that are intrusive and unwanted experiences, 
while compulsions are repetitive behaviors or mental acts 
that an individual feels compelled to perform in response 
to an obsession or according to a set of rules that must be 
rigidly applied. Because it is a chronic disease character-
ized by obsessions and compulsions, OCD causes discom-
fort to the patient and his/her family27 and was ranked as 
the fourth most common psychiatric disorder, affecting 
approximately 1–3% of the global population28. It is also 
known that the disease is associated with dysfunction in 
the frontostriatal circuit, including the dorsolateral pre-
frontal cortex, orbitofrontal cortex, and medial prefrontal 
cortex, as well as the supplementary motor area, supple-
mental gyrus, anterior cingulate gyrus and basal ganglia29. 
An interesting fact is that only 40-60% of patients respond 
to pharmacological treatment and cognitive behavioral 
therapy30, justifying the use of new techniques in order to 
reduce resistance to treatment in these patients. Further 
research is still needed to provide a better understanding 
of the neural circuits involved in this disorder, since as-
pects of its etiology and pathophysiology remain unknown. 
Recent studies with rTMS emphasize that inhibitory ap-
plication at a low frequency (1 Hz) on the supplementary 
motor area improves symptoms and increases the motor 
threshold31 and intracortical inhibition measured by the 
matched magnetic pulses technique32, the latter consid-
ered to be dependent on GABAergic mechanisms. These 
results corroborate the findings of Gomes et al.33 who, 
in a recent randomized, double-blind study of OCD pa-
tients, showed that those who received rTMS on the sup-
plementary motor area over two weeks had 35% improve-
ment in OCD symptoms (Y-BOCS scale). Also in relation to 
symptoms of anxiety, there was a reduction in symptoms 
of 19.6% in the tDCS group compared to 9.5% in the group 
undergoing control stimulation, according to the anxiety 
scale (Hamilton Rating Scale for Anxiety - HRAS-14) after 
two weeks of stimulation. As to the symptoms of depres-
sion, they found no significant difference between tDCS 
and control groups on the Hamilton Scale for Depression 
(HRSD-24). In recent literature reviews, Berlim et al.34 and 
Senço et al.35 also observed that response rates among pa-
tients who received low-frequency rTMS on the orbito-
frontal cortex or supplementary motor area vary between 
35% and 13%, making these areas promising targets for re-
ducing the symptoms of OCD, but studies are still incipi-
ent, as pointed out by some authors14.
NEUROMODULATION AND POST-TRAUMATIC 
STRESS DISORDER
In addition to OCD, a few studies have also investigat-
ed the effects of transcranial stimulation on PTSD. This 
is a psychiatric condition that occurs in people who have 
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witnessed events involving active threat of death or seri-
ous injury, or a threat to the physical safety of themselves 
or others36 and is characterized by three symptom clusters: 
re-experience, avoidance and hyperarousal, resulting in so-
cial or occupational dysfunction. The symptoms must be 
present for at least a month, and may last for years. It is also 
a condition in which exposure to a risk against life results in 
a set of intrusive memories, where the individual experienc-
es events associated with stress37. Epidemiological studies 
estimate that 7.8% of the US population suffer from PTSD 
at some point in their lives38, suggesting a psychosocial and 
economic loss exceeding US$ 3 billion in lost productivity 
to the US every year36. 
Pharmacological studies have shown that reduced glu-
tamatergic neurotransmission, by AMPA receptor block-
age, results in anxiolytic effects. In PTSD patients, this ef-
fect results in reduced flashbacks and nightmares, typical 
symptoms of the disorder. Regarding the hypothalamic-
pituitary-adrenal axis, hypocortisolemia is different from 
other anxiety disorders. It is not exactly known why the 
reduction occurs, but it has been found that when cor-
tisol levels are lower in PTSD, the severity of symptoms 
is greater. However, although many drugs have demon-
strated therapeutic benefit in humans with PTSD39 and 
many of these drugs have been shown to be capable of 
preventing anxious behavior and cognitive impairment 
in rats with stress40, not all patients respond to pharma-
cological treatment options for PTSD. For this reason, 
non-pharmacological treatments and noninvasive meth-
ods such as rTMS and tDCS have been tried41.
A few studies have shown that administration of 
low-frequency rTMS on the right dorsolateral prefrontal 
cortex is beneficial for improving the symptoms of PTSD9, 
by decreasing cortical excitability. Garcia-Toro et al.42 
demonstrated that refractory PTSD patients showed an 
improvement of clinical symptoms after 10 sessions of 
low-frequency rTMS (1 Hz) applied to the right dorso-
lateral prefrontal cortex. In a complementary manner, 
Osuch et al.43 demonstrated that patients who had 20 ses-
sions of low-frequency rTMS (1 Hz) on the right dorsolat-
eral prefrontal cortex and PTSD exposure therapy showed 
a reduction in the symptomatic and psychophysiological 
effects of PTSD, as assessed by the Hamilton Depression 
Rating Scale, the Impact of Events Scale and the Clinical 
Administered PTSD Scale. Curiously, a group of research-
ers has been conducting experiments using high-frequency 
rTMS (10 Hz) instead of low frequency rTMS in patients 
with PTSD, and has also reported positive results9. Such ex-
periments, however, still need to be replicated by other re-
searchers, on the basis of variable conflicting results.
Correlation with neuroimaging studies
Neuroimaging studies on rTMS and PTSD have shown 
increased oxygenation in the right prefrontal cortex when 
participants are exposed to experiences that remind them 
of the traumatic experiences, suggesting that overactivity on 
the right side in PTSD is associated with the role of the right 
hemisphere in anxiety and other adverse emotional experi-
ences44. Thus, low-frequency rTMS (1 Hz) might decrease ac-
tivity in the cortical areas of the right hemisphere, which in 
turn might improve the abnormalities and reduce cerebral 
functional asymmetries associated with PTSD43. Still, hyper-
activation of the amygdala and the rostral region of the cin-
gulate cortex is observed in these patients, and the higher 
the activation of these regions, the greater the severity of the 
symptoms of PTSD.
These findings therefore suggest that rTMS on the 
right dorsolateral prefrontal cortex seems to be well suit-
ed to become an effective tool in the treatment of PTSD; 
moreover, there is evidence that rTMS produces anxiolyt-
ic action in humans45. Berlim et al.46 reviewed several ran-
domized controlled studies conducted between 1995 and 
2013 and found that studies on PTSD patients in which 
rTMS was applied on the right dorsolateral prefrontal cor-
tex pointed to significant differences from patients under-
going sham rTMS. In addition, there were differences in 
the symptoms of anxiety and depression among PTSD pa-
tients before and after rTMS. Additionally, Karsen et al.47 
conducted a review of published reports including a to-
tal of 132 patients to evaluate the efficacy of rTMS in the 
treatment of PTSD. Based on the review, it was found that 
the variables most often studied were: a) treatment of the 
right or left cerebral hemisphere; b) stimulation frequency 
(0.3, 1, 5, 10 or 20 Hz); c) anatomical location; d) number of 
stimulation pulses; e) combination of rTMS with exposure. 
All studies stimulated pre-frontal regions.
Neuromodulation for PTSD and the right-left dilemma
Boggio et al.48 demonstrated that high-frequency rTMS 
(20Hz) of either the right or left cerebral hemisphere can 
be effective in reducing the symptoms of PTSD. In con-
trast, some authors have observed that low-frequency 
rTMS (1 Hz) on the right dorsolateral prefrontal cor-
tex43 seems to be more effective. Again, however, Cohen 
et al.9, upon comparing low-frequency rTMS (1Hz) and 
high-frequency rTMS (10Hz) on the right dorsolateral 
prefrontal cortex, concluded that high-frequency rTMS 
showed greater improvement of PTSD symptoms com-
pared to low-frequency rTMS (29.3 % and 10.4% respec-
tively). Furthermore, Rosenberg et al.49 compared the ef-
fect of low-frequency and high-frequency rTMS (1 Hz and 
5 Hz, respectively) and found low-frequency rTMS on the 
left dorsolateral prefrontal cortex to be efficient in reduc-
ing depressive symptoms, but not PTSD symptoms.
Although studies have demonstrated effects on corti-
cal activation for both high-frequency and low-frequency 
stimulation, and treatment of both the right and left dor-
solateral prefrontal cortices have been shown to reduce 
833Iannone A et al. Clinical use of TMS and tDCS
symptoms of PTSD, it is not yet understood how stimula-
tion of the dorsolateral prefrontal cortex affects this neu-
ral circuitry. Regarding the rTMS mechanism of action 
in PTSD, it is known that: a) stimulating the right dorso-
lateral prefrontal cortex with a high frequency activates 
the hypothalamic-pituitary-adrenal axis, inhibiting exces-
sive autonomic response and suppressing activity of the 
amygdala9; b) stimulating the right dorsolateral prefron-
tal cortex with a low frequency inhibits the right hemi-
sphere, reducing hyperactivity of the right prefrontal cor-
tex in patients with PTSD. Thus, both low-frequency and 
high-frequency rTMS, when applied to the right side, are 
potentially well suited to reduce the symptoms of PTSD.
Limitations of PTSD and PTSD-depression studies
Regarding the limitations of PTSD studies, Karsen et al.47 
suggest that, although there are studies in which both fre-
quencies can contribute to a decrease in the symptoms of 
PTSD, one frequency may be better than the other, and fur-
ther research is therefore needed in this area. Furthermore, 
the small number of subjects in these analyses limits any gen-
eralization of the findings, which increases the need for fur-
ther studies with larger samples and improved stimulation 
parameters50; moreover, the mechanism of action of rTMS in 
anxiety disorders needs to be further clarified, by combining 
TMS with neuroimaging51.
In addition to treatment with rTMS, PTSD is also treat-
ed through exposure to objects and events that induce anxi-
ety and memories of aversive episodes52, but in a controlled 
environment so that patients know that they are not in dan-
ger. Finally, the frequent coexistence of anxiety and mood 
disorders justifies the concomitant study, for example, of 
panic disorder (PD) and major depressive disorders with 
rTMS. Many researchers have been interested in both psy-
chiatric disorders, since they lead to a decrease in function-
ality, resulting in increased morbidity and suicide rates53.
NEUROMODULATION AND PANIC DISORDER
Although less numerous, studies have also been pub-
lished on the effects of transcranial stimulation in patients 
with PD. For example, low-frequency rTMS (1Hz) on the right 
dorsolateral prefrontal cortex seems to lessen the symptoms 
of panic in these patients32. There seems to be an activation 
asymmetry, so that, in PD patients, the right hemisphere 
appears to be more active than the left in the dorsolateral 
prefrontal cortex area54.
Right-sided low-frequency rTMS and PD
To test the clinical effects of low-frequency rTMS 
(1 Hz) on the right dorsolateral prefrontal cortex of pa-
tients with PD and depression who are resistant or in-
tolerant to medication, Zwanzger et al.55 observed that 
after two weeks of rTMS treatment there was significant 
improvement in symptoms of anxiety and depression, 
corroborating the findings of Mantovani et al.56 Later, 
Mantovani et al.32 demonstrated that, after four weeks of 
low-frequency rTMS stimulation of the right dorsolater-
al prefrontal cortex, patients who received real treatment 
fared better than those who received only sham stimu-
lation. It can therefore be concluded that low-frequency 
rTMS on the right dorsolateral prefrontal cortex improves 
symptoms of major depression and anxiety disorders55. 
Low-frequency rTMS (1Hz) on the right dorsolateral pre-
frontal cortex decreased symptoms of panic according to 
Li et al.57, although the difference was not significant be-
tween patients who received rTMS and sham rTMS, mea-
sured by the Panic Disorder Severity Scale.
Left-sided high-frequency rTMS stimulation and PD
In contrast, Pallanti and Bernardi50 concluded that 
high-frequency rTMS on the right dorsolateral prefron-
tal cortex reduced symptoms in anxiety disorders and had 
positive results in patients with PTSD and PD, while the 
case study by Sakkas et al.58 in which high-frequency rTMS 
(10-20Hz) was administered to the left dorsolateral pre-
frontal cortex in a patients with PD who was resistant to 
pharmacological treatment, also showed an improvement 
in symptoms. These findings are in keeping with other stud-
ies that compared high-frequency rTMS over the left dor-
solateral prefrontal cortex to the effects of antidepressants. 
Additionally, Dresler et al.59 demonstrated improvements in 
symptoms of patients diagnosed with PD as a result of three 
weeks of high-frequency rTMS over the left dorsolateral 
prefrontal cortex, confirming the study by Guaiana et al.60, 
which found an improvement in the symptoms of anxiety 
on the Panic Disorder Severity Scale.
A limitation of the rTMS method in anxiety disorders is 
that its impact is on the cortical surface layers, and it is not 
possible to directly stimulate more distant cortical and sub-
cortical areas that are relevant to the pathogenesis of anxiety 
disorders. Thus, further studies are recommended to deter-
mine the role of tDCS in the treatment of anxiety disorders, 
since it is a less focal stimulation and may influence deeper 
neuronal circuits.
In conclusion, both TMS and tDCS appear to be safe and 
useful neuromodulatory techniques with potential applica-
tion in the treatment of anxiety disorders, as well as a num-
ber of other neuropsychiatric disorders. However, as is well 
illustrated by this review of anxiety disorders, larger clinical 
trials are needed if consensus is to be reached regarding in-
dications, optimal treatment protocols and clinical relevance 
of these non-pharmacological interventions. Morevover, cau-
tion should be exercised to avoid abusive use of these pow-
erful neuromodulatory techniques, due to the uncertain-
ties about their exact mechanism of action and possible 
long-term side effects.
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